Does SummaCare Cover Eliquis?

Understanding SummaCare's Formulary and How Eliquis Fits

SummaCare is a regional managed care organization headquartered in Akron, Ohio, serving commercial, Medicare Advantage, and Medicaid populations across northeastern Ohio. Each SummaCare product line maintains its own prescription drug formulary, and Eliquis placement varies by plan type.

On most SummaCare commercial plans, Eliquis appears on the preferred brand tier (Tier 3). This placement reflects the drug's clinical profile and its position among direct oral anticoagulants. The American College of Cardiology and American Heart Association 2019 guidelines recommend DOACs, including apixaban, over warfarin for most patients with non-valvular atrial fibrillation, citing a lower risk of intracranial hemorrhage [1]. That guideline endorsement supports formulary inclusion, but it does not guarantee the lowest copay tier.

SummaCare Medicare Advantage plans follow CMS formulary requirements, which mandate coverage of "all or substantially all" anticoagulants. Eliquis appears on these formularies as well, though it may be placed on a higher specialty tier with cost-sharing that includes coinsurance (typically 25% to 33%) rather than a flat copay. Checking your plan's Evidence of Coverage document or calling the number on your member ID card gives you the most accurate, current tier placement.

For SummaCare Medicaid managed care enrollees, coverage of Eliquis depends on the Ohio Department of Medicaid's preferred drug list. Ohio Medicaid does include apixaban, but prior authorization criteria can be stricter than those on commercial plans [2].

What You Can Expect to Pay Out of Pocket

The monthly cost of Eliquis under a SummaCare plan depends on your tier placement, deductible status, and whether you have reached any out-of-pocket maximum. A standard 30-day supply of Eliquis 5 mg twice daily carries a retail price of roughly $580 to $620 without insurance, according to FDA-reported pricing data [3].

With SummaCare commercial coverage at a Tier 3 placement, most members report copays between $35 and $90 for a 30-day fill. Plans with higher deductibles may require you to pay full price until the deductible is satisfied. Some high-deductible health plans paired with HSAs treat Eliquis as a preventive medication for certain diagnoses, which can reduce pre-deductible costs.

Bristol-Myers Squibb offers a manufacturer copay assistance program that can reduce out-of-pocket costs to as little as $10 per month for eligible commercially insured patients. This card does not apply to government-funded insurance, including Medicare Part D, Medicaid, or Tricare. SummaCare Medicare Advantage members may instead qualify for the Extra Help (Low-Income Subsidy) program through CMS, which caps monthly drug copays at $4.50 to $11.20 depending on subsidy level.

Mail-order pharmacy options through SummaCare's pharmacy benefit manager can also reduce per-fill costs. A 90-day mail-order supply typically costs 2.0 to 2.5 times the 30-day copay rather than three times, saving roughly 15% to 30% over quarterly refills at retail.

Prior Authorization and Step Therapy Requirements

SummaCare, like most managed care organizations, applies utilization management tools to control spending on brand-name anticoagulants. For Eliquis specifically, the two most common requirements are prior authorization (PA) and step therapy.

Prior authorization for Eliquis on SummaCare plans typically requires the prescriber to confirm one or more of the following: a diagnosis of non-valvular atrial fibrillation with a CHA₂DS₂-VASc score of 2 or greater in men or 3 or greater in women; active deep vein thrombosis or pulmonary embolism requiring treatment; or post-surgical prophylaxis following hip or knee replacement [4]. The prescriber submits documentation, and SummaCare's pharmacy team typically responds within 24 to 72 hours.

Step therapy protocols on certain SummaCare plans may require a trial of warfarin before approving Eliquis. This requirement has become less common since the ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, P<0.001), with 31% fewer major bleeding events [5]. Many prescribers successfully appeal step therapy denials by citing this evidence.

If your SummaCare plan denies coverage, you have the right to file an internal appeal. The denial letter includes instructions and deadlines. CMS requires Medicare Advantage plans to process standard appeals within 7 calendar days and expedited appeals within 72 hours. Commercial plan appeal timelines are governed by Ohio Department of Insurance regulations.

Clinical Evidence Supporting Eliquis Coverage

Insurance formulary decisions rely heavily on clinical trial data, and Eliquis has one of the strongest evidence bases among DOACs. Understanding this evidence can help you or your prescriber argue for coverage if it is initially denied.

The ARISTOTLE trial, published in the New England Journal of Medicine in 2011, randomized 18,201 patients with atrial fibrillation to apixaban 5 mg twice daily or dose-adjusted warfarin [5]. Apixaban was superior for the primary endpoint of stroke or systemic embolism (hazard ratio 0.79, 95% CI 0.66 to 0.95). It also reduced all-cause mortality by 11% (3.52% vs. 3.94% per year) and major bleeding by 31% (2.13% vs. 3.09% per year). These results established apixaban as the DOAC with the most favorable bleeding profile relative to warfarin.

For venous thromboembolism, the AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for recurrent VTE (2.3% vs. 2.7%), while causing 69% less major bleeding (0.6% vs. 1.8%, P<0.001) [6]. Dr. Giancarlo Agnelli, the trial's lead investigator, noted: "The reduction in major bleeding with apixaban compared with conventional therapy was consistent across all prespecified subgroups."

The ADVANCE-3 trial (N=5,407) demonstrated apixaban's superiority over enoxaparin for preventing VTE after total knee replacement, with a relative risk reduction of 62% for the primary composite endpoint [7]. These three landmark trials collectively support apixaban coverage across its three FDA-approved indications.

A 2022 Cochrane systematic review of DOACs versus warfarin for atrial fibrillation confirmed that apixaban had the lowest rates of major bleeding among all four approved DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) [8].

How Eliquis Compares to Other Anticoagulants on SummaCare Formularies

SummaCare formularies include several anticoagulant options, and understanding the alternatives can help you evaluate whether Eliquis is worth the higher copay or whether a switch might make financial sense without sacrificing clinical outcomes.

Warfarin is universally covered on Tier 1 (generic) with copays of $0 to $15 per month. It remains effective for stroke prevention in atrial fibrillation, but it requires regular INR monitoring (typically every 2 to 4 weeks), has numerous drug and food interactions, and carries a higher risk of intracranial hemorrhage compared to DOACs. The 2019 AHA/ACC/HRS guideline states: "For patients with AF who are eligible for oral anticoagulation with a DOAC, a DOAC is recommended over warfarin" [1].

Xarelto (rivaroxaban) often shares the same tier as Eliquis on SummaCare plans. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention but did not demonstrate superiority [9]. Rivaroxaban had higher rates of GI bleeding compared to warfarin (3.2% vs. 2.2% per year). Its once-daily dosing is convenient, but it must be taken with food for adequate absorption.

Savaysa (edoxaban) appears on some SummaCare formularies at a comparable or lower tier than Eliquis. The ENGAGE AF-TIMI 48 trial (N=21,105) showed edoxaban was non-inferior to warfarin, with lower rates of bleeding and cardiovascular death [10]. One limitation is that edoxaban is contraindicated in patients with creatinine clearance above 95 mL/min, which excludes some younger, healthier patients.

Pradaxa (dabigatran) is the only DOAC with a specific reversal agent (idarucizumab). It sits on a similar formulary tier to Eliquis on most SummaCare plans. The RE-LY trial (N=18,113) showed that dabigatran 150 mg twice daily was superior to warfarin for stroke prevention but had higher rates of GI bleeding [11].

Strategies to Reduce Your Eliquis Costs on SummaCare

Several practical steps can lower what you pay for Eliquis, even if your SummaCare plan places it on a higher tier.

First, ask your prescriber to submit a formulary exception request. If you have tried and failed warfarin or another lower-tier anticoagulant, or if you have a documented clinical reason why Eliquis is medically necessary (such as a history of intracranial hemorrhage on warfarin, poor INR control defined as time in therapeutic range below 60%, or inability to attend regular INR monitoring appointments), your prescriber can request that SummaCare cover Eliquis at a lower tier. The ACC 2023 Expert Consensus Decision Pathway on anticoagulant selection supports DOAC use when warfarin TTR falls below 65% [12].

Second, enroll in the Bristol-Myers Squibb/Pfizer copay assistance program if you have commercial insurance. This program has saved eligible patients an average of $500 per year on Eliquis copays according to the manufacturer's published data.

Third, consider a 90-day mail-order supply. SummaCare's PBM partner typically offers a discount on 90-day fills compared to three separate 30-day retail purchases. The savings can amount to one month's copay free over the course of a year.

Fourth, if you are on a SummaCare Medicare Advantage plan, check whether you qualify for the Medicare Part D Extra Help program. In 2026, individuals with annual income below $22,590 (or $30,660 for couples) and limited assets may qualify for substantial copay reductions [13].

Fifth, ask your prescriber about the 2.5 mg twice-daily dose if clinically appropriate. The FDA-approved labeling specifies this reduced dose for patients meeting at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher [14]. The lower dose uses the same tablet count, so the copay is identical, but some specialty pharmacies offer different pricing for the 2.5 mg strength.

What to Do If SummaCare Denies Your Eliquis Prescription

A denial is not the final word. SummaCare members have a clearly defined appeals process, and denials for Eliquis are frequently overturned when supported by clinical documentation.

Start by reading the denial letter carefully. It will specify the reason for denial (formulary exclusion, prior authorization not met, step therapy requirement, or quantity limit exceeded) and the deadline for appeal. Commercial plan members typically have 180 days to file an internal appeal. Medicare Advantage members have 60 days.

Your prescriber should submit a letter of medical necessity that includes your diagnosis, relevant lab values (such as CHA₂DS₂-VASc score for AFib, creatinine clearance for dosing), any prior anticoagulant trials and their outcomes, and citations to guideline recommendations. Including the ARISTOTLE trial data showing apixaban's superiority to warfarin for both efficacy and safety strengthens the appeal considerably.

If the internal appeal is denied, you can request an external review. Ohio law requires commercial insurers to offer independent external review by a physician reviewer not affiliated with SummaCare. For Medicare Advantage plans, the appeal goes to an Independent Review Entity contracted by CMS.

During the appeals process, ask your prescriber about a bridge supply. Many SummaCare plans allow a temporary (typically 30-day) fill of a denied medication while the appeal is pending, especially when interruption of anticoagulation poses a stroke risk.

Eliquis Dosing and Administration Basics

Correct dosing matters both for clinical outcomes and insurance coverage, because prior authorization criteria often specify dose limits.

For stroke prevention in non-valvular atrial fibrillation, the standard dose is 5 mg twice daily [14]. The reduced dose of 2.5 mg twice daily applies to patients meeting at least two of the three criteria mentioned above. Taking the wrong dose can reduce efficacy or increase bleeding risk.

For treatment of DVT or PE, the regimen begins with 10 mg twice daily for 7 days, then transitions to 5 mg twice daily. For extended prophylaxis after completing 6 months of treatment, the dose drops to 2.5 mg twice daily. SummaCare prior authorization for VTE treatment typically approves the full 6-month course upfront, but extended prophylaxis beyond 6 months may require a new PA submission.

For post-surgical prophylaxis after hip or knee replacement, the dose is 2.5 mg twice daily, initiated 12 to 24 hours after surgery. The recommended duration is 35 days after hip replacement and 12 days after knee replacement, per the ADVANCE trial program [7].

Eliquis can be taken with or without food. Tablets should not be crushed for patients who can swallow whole tablets, but for patients with difficulty swallowing, the tablets can be crushed and suspended in water, apple juice, or applesauce and delivered through a nasogastric tube per the FDA label. This detail becomes relevant when hospitals submit PA requests for inpatient-to-outpatient transitions on SummaCare plans.

Monitoring and Follow-Up While on Eliquis

Unlike warfarin, Eliquis does not require routine coagulation monitoring. This is one of its major advantages and a cost-saving factor that SummaCare's formulary committee weighs during coverage decisions. Eliminating biweekly or monthly INR checks saves approximately $300 to $600 per year in lab and office visit costs, partially offsetting the higher drug copay.

Prescribers should check renal function (serum creatinine and estimated CrCl) at baseline and at least annually, since apixaban is partially renally cleared (approximately 27% renal excretion) [14]. Patients with rapidly changing renal function, such as those with acute kidney injury, heart failure exacerbations, or dehydration, may need more frequent monitoring.

A complete blood count at baseline and periodically during treatment helps detect occult bleeding. The International Society on Thrombosis and Haemostasis recommends checking hemoglobin at least every 12 months and more frequently in patients at high bleeding risk [15].

Hepatic function testing (ALT, AST, bilirubin) at baseline is recommended because severe hepatic impairment (Child-Pugh C) is a contraindication to apixaban use. SummaCare PA criteria may require documentation of hepatic function as part of the approval process.

Patients on Eliquis should carry a card or wear a medical alert bracelet indicating anticoagulant use. In emergencies requiring reversal, andexanet alfa (Andexxa) is the FDA-approved reversal agent for apixaban, though its availability varies by hospital and its cost exceeds $24,000 per treatment course, a factor that SummaCare covers under medical (not pharmacy) benefits when administered in an inpatient setting.